RecruitingNot Applicable

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

United States2,000 participantsStarted 2024-01-02

Plain-language summary

This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and: * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy OR * Subjects who have or have had a solid tumor diagnosis and any of the following: * At least 4 months of exposure to a PARP inhibitor * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm Exclusion Criteria: * Individuals with a life expectancy of less than 6 months

What they're measuring

Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients

Timeframe: Through study completion, up to 5 years

Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors

Timeframe: Through study completion, up to 5 years

Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN

Timeframe: Through study completion, up to 5 years

Trial details

NCT IDNCT06295965

SponsorUniversity of Washington

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-12-31

Contact for this trial

Swisher Lab Research Coordinators

206-616-8927 swisherlabrc@uw.edu

View on ClinicalTrials.gov More Recurrent Fallopian Tube Carcinoma trials

Plain-language summary

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients

Timeframe: Through study completion, up to 5 years

Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors

Timeframe: Through study completion, up to 5 years

Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN

Timeframe: Through study completion, up to 5 years